PHASE II STUDY EVALUATING THE ACTIVITY AND TOXICITY OF A BIWEEKLY SCHEDULE OF GEMCITABINE AND PACLITAXEL IN ANTHRACYCLINE-PRETREATED BREAST CANCER

被引：0
|
作者：
Spinelli, G. P. [1 ]
Di Seri, M. [1 ]
Mezi, S. [1 ]
Oliveti, A. [1 ]
Tomao, F. [1 ]
Petricola, F. [1 ]
Rosati, S. [1 ]
Ricciardi, S. [1 ]
Coletta, D. [1 ]
Romiti, A. [1 ]
Frati, L. [1 ]
Tomao, S. [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [21] Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
    A Lortholary
    T Delozier
    A Monnier
    H Bourgeois
    P Bougnoux
    N Tubiana-Mathieu
    J Ch Riffaud
    D Besson
    V Lotz
    E Gamelin
    British Journal of Cancer, 2003, 88 : 1669 - 1674
  • [22] Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
    Lortholary, A
    Delozier, T
    Monnier, A
    Bourgeois, H
    Bougnoux, P
    Tubiana-Mathieu, N
    Riffaud, JC
    Besson, D
    Lotz, V
    Gamelin, E
    BRITISH JOURNAL OF CANCER, 2003, 88 (11) : 1669 - 1674
  • [23] Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study
    Peter Schmid
    Volker Heilmann
    Carsten-Oliver Schulz
    Annette Dieing
    Silvia Lehenbauer-Dehm
    Christian Jehn
    Orhan Sezer
    Kurt Possinger
    Bernd Flath
    Journal of Cancer Research and Clinical Oncology, 2005, 131 : 568 - 574
  • [24] MITOMYCIN-C AND MITOXANTRONE IN ANTHRACYCLINE-PRETREATED ADVANCED BREAST-CANCER PATIENTS - A PHASE-II STUDY
    PERRONE, F
    DEPLACIDO, S
    CARLOMAGNO, C
    GRAVINA, A
    DELAURENTIIS, M
    DELMASTRO, L
    GRIDELLI, C
    PAGLIARULO, C
    BIANCO, AR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (03): : 218 - 222
  • [25] Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study
    Schmid, P
    Heilmann, V
    Schulz, CO
    Dieing, A
    Lehenbauer-Dehm, S
    Jehn, C
    Sezer, O
    Possinger, K
    Flath, B
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (09) : 568 - 574
  • [26] Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer
    Suzuma, T
    Sakurai, T
    Yoshimura, G
    Umemura, T
    Tamaki, T
    Naito, Y
    ANTI-CANCER DRUGS, 2000, 11 (07) : 569 - 571
  • [27] Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer
    Susnjar, S.
    Bosnjak, S.
    Radulovic, S.
    Stevanovic, J.
    Gajic-Dobrosavljevic, M.
    Kreacic, M.
    JOURNAL OF BUON, 2007, 12 (02): : 189 - 196
  • [28] High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients
    Vici, P
    Capomolla, E
    Foggi, P
    Carpano, S
    Conti, F
    Paoletti, G
    Cauchi, C
    Giacinti, L
    Leonetti, C
    Giannarelli, D
    Lopez, M
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2006, 25 (01): : 39 - 44
  • [29] A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer
    Delozier, Thierry
    Guastalla, Jean-Paul
    Yovine, Alejandro
    Levy, Christelle
    Chollet, Philippe
    Mousseau, Mireille
    Delva, Remy
    Coeffic, David
    Vannetzel, Jean-Michel
    Zazzi, Eliette-Sudriez
    Brienza, Silvano
    Cvitkovic, Esteban
    ANTI-CANCER DRUGS, 2006, 17 (09) : 1067 - 1073
  • [30] A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment
    Xu, Binghe
    Shen, Zhenzhou
    Jiang, Zefei
    Guan, Zhongzhen
    Zhang, Xiaoqing
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (04) : 320 - 329
12345